Research programme: chimerasome nanocage therapeutics - Sevion Therapeutics

Drug Profile

Research programme: chimerasome nanocage therapeutics - Sevion Therapeutics

Alternative Names: CH 001; SVN-003

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Fabrus
  • Developer Sevion Therapeutics
  • Class Antibodies; Insulins; Pancreatic hormones; Peptides; Proteins; Small interfering RNA; Small molecules
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Diabetes mellitus

Most Recent Events

  • 24 Nov 2014 Sevion Therapeutics enters into a research agreement with Avidity NanoMedicines LLC regarding the use of Sevion's chimerasome technology to deliver nucleic acids
  • 09 Sep 2014 Senesco Technologies changes name to Sevion Therapeutics
  • 27 May 2014 Research programme: diabetes mellitus therapeutics - Fabrus is available for licensing as of 27 May 2014. http://www.fabrus.net/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top